Patents by Inventor Max GORDON

Max GORDON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA
    Publication number: 20230279503
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Application
    Filed: May 12, 2023
    Publication date: September 7, 2023
    Inventors: Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
  • Assays and methods for selecting a treatment regimen for a subject with leukemia
    Patent number: 11746386
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: September 5, 2023
    Assignees: CELATOR PHARMACEUTICALS, INC., OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Max Gordon, Paul Tardi, Jeffrey Tyner, Lawrence Mayer
  • ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA
    Publication number: 20210246512
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Application
    Filed: February 11, 2021
    Publication date: August 12, 2021
    Applicants: Celator Pharmaceuticals, Inc., Oregon Health & Science University
    Inventors: Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
  • Assays and methods for selecting a treatment regimen for a subject with leukemia
    Patent number: 10927418
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 23, 2021
    Assignees: Celator Pharmaceuticals, Inc., Oreoon Health & Science University
    Inventors: Max Gordon, Paul Tardi, Jeffrey Tyner, Lawrence Mayer
  • ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA
    Publication number: 20180327854
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Application
    Filed: November 10, 2016
    Publication date: November 15, 2018
    Applicants: Celator Pharmaceuticals Inc., OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER